These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33443971)

  • 1. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun.
    Sarafidis P; Ortiz A; Ferro CJ; Halimi JM; Kreutz R; Mallamaci F; Mancia G; Wanner C;
    J Hypertens; 2021 Jun; 39(6):1090-1097. PubMed ID: 33443971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease.
    Sarafidis P; Pella E; Kanbay M; Papagianni A
    Curr Med Chem; 2023; 30(18):2039-2060. PubMed ID: 36028970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
    Weir MR; McCullough PA; Buse JB; Anderson J
    Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review.
    Maxson R; Starr J; Sewell J; Lyas C
    Clin Ther; 2024 Jan; 46(1):e23-e28. PubMed ID: 37951783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
    Fletcher RA; Jongs N; Chertow GM; McMurray JJV; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Rockenschaub P; Rossing P; Correa-Rotter R; Toto RD; Vaduganathan M; Wheeler DC; Heerspink HJL; Neuen BL
    J Am Soc Nephrol; 2023 Dec; 34(12):1965-1975. PubMed ID: 37876229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and meta-analysis.
    Reyes-Farias CI; Reategui-Diaz M; Romani-Romani F; Prokop L
    PLoS One; 2023; 18(11):e0295059. PubMed ID: 38019892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA.
    Mark PB; Sarafidis P; Ekart R; Ferro CJ; Balafa O; Fernandez-Fernandez B; Herrington WG; Rossignol P; Del Vecchio L; Valdivielso JM; Mallamaci F; Ortiz A; Nistor I; Cozzolino M
    Nephrol Dial Transplant; 2023 Oct; 38(11):2444-2455. PubMed ID: 37230946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
    Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
    J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A
    Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.
    Säemann M; Cejka D; Schmaldienst S; Rosenkranz AR; Mayer G
    Wien Klin Wochenschr; 2023 Feb; 135(3-4):97-109. PubMed ID: 36251099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
    J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease.
    Del Vecchio L; Beretta A; Jovane C; Peiti S; Genovesi S
    Drugs; 2021 Sep; 81(13):1491-1511. PubMed ID: 34363606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease].
    Shamkhalova MS; Sukhareva OY; Shestakova MV
    Ter Arkh; 2022 Nov; 94(10):1188-1196. PubMed ID: 36468994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
    Khoo CM; Deerochanawong C; Chan SP; Matawaran B; Sheu WH; Chan J; Mithal A; Luk A; Suastika K; Yoon KH; Ji L; Man NH; Pollock C
    Diabetes Obes Metab; 2021 Feb; 23(2):299-317. PubMed ID: 33155749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.